Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: Comparison with pravastatin

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 280, Issue 6 49-6, 2001, Pages

  Satoh, Kumi ^a   Shirota, Fumiyo ^a   Tsunajima, Takahiko ^a   Beinlich, Cathy J ^b   Morgan, Howard E ^b   Ichihara, Kazuo ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Mitogen activated protein kinase

Indexed keywords

ATORVASTATIN; DNA; MITOGEN ACTIVATED PROTEIN KINASE; PENTOBARBITAL; PRAVASTATIN; RNA; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HEART DEVELOPMENT; HEART PERFUSION; HEART RATE; HEART VENTRICLE WALL; HEART WEIGHT; NEWBORN; NEWBORN PERIOD; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SWINE;

EID: 0034989343     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2001.280.6.h2746     Document Type: Article

References (35)

1. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells
2. Mechanisms of rapid growth in the neonatal pig heart
3. Angiotensin II and left ventricular growth in new born pig heart
4. Direct vascular effects of HMG-CoA reductase inhibitors
5. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)
6. Acceleration ribosome formation and growth in neonatal pig hearts
7. The composition of fetal and maternal blood during parturition in the ewe
8. Non-lipid-related effects of 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
9. The mitogen-activated protein kinase signal transduction pathway
10. Lovastatin decreases coenzyme Q levels in humans
11. Pravastatin, lipids, and major coronary events
12. Regulation of the mevalonate pathway
13. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs
14. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
15. Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells. Probable involvement of small GTP-binding proteins
16. Protein measurement with Folin phenol reagent
17. Posttranslational modification of proteins by isopreoids in mammalian cells
18. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence
19. The determination of nucleic acids
20. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cell
21. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
22. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
23. Regulation of HMG-CoA reductase
24. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level
25. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro
26. A neural factor involved in increase of the glycogen phosphorylase activity after coronary ligation in both ischemic and nonischemic areas of the dog heart
27. Lipophilic HMG-CoA reductase inhibitors worsen myocardial stunning in dogs
28. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts
29. Genetic and pharmacological suppression of oncogenic mutations in Ras genes of yeast and humans
30. The MAPK signaling cascade
31. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
32. Substances interfering with spectrophotometric estimation of nucleic acids and their elimination by the two-wavelength method
33. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial (CCAIT)
34. The molecular mechanism of cardiac hypertrophy and failure
35. Development and proliferative capacity of cardiac muscle cell